Page last updated: 2024-12-06
losoxantrone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
losoxantrone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72116 |
| CHEMBL ID | 83520 |
| SCHEMBL ID | 61319 |
| MeSH ID | M0144496 |
Synonyms (23)
| Synonym |
|---|
| CHEMBL83520 , |
| c-1941 , |
| NCI60_003246 |
| losoxantrone [inn:ban] |
| losoxantrone |
| anthrapyrazolone |
| anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)- |
| bdbm50240660 |
| 7-hydroxy-2-[2-(2-hydroxy-ethylamino)-ethyl]-5-[2-(2-hydroxy-ethylamino)-ethylamino]-2h-dibenzo[cd,g]indazol-6-one |
| bianthrazole |
| 47kph00809 , |
| 88303-60-0 |
| unii-47kph00809 |
| anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino) |
| 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)anthra(1,9-cd)pyrazol-6(2h)-one |
| losoxantrone [who-dd] |
| losoxantrone [inn] |
| SCHEMBL61319 |
| DTXSID60236949 |
| Q21098832 |
| bianthrazole; biantrazole; c 1941; losoxantrone |
| 7-hydroxy-2-[2-(2-hydroxyethylamino)ethyl]-5-[2-(2-hydroxyethylamino)ethylamino]anthra[1,9-cd]pyrazol-6(2h)-one |
| 6-hydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(2-hydroxyethylamino)ethylamino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one |
Research Excerpts
Overview
Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Losoxantrone is an anthrapyrazole derivative in Phase III development in the U.S. " | ( Elimination pathways of [14C]losoxantrone in four cancer patients. Chai, MF; Davidson, AF; Finizio, M; Joshi, AS; Pieniaszek, HJ; Ratain, MJ; Richards, LE; Vogelzang, NJ; Vokes, EE, 2001) | 2.04 |
| "Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. " | ( Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Goh, BC; Joshi, A; Ratain, MJ; Vokes, EE, 2002) | 2.03 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Lethality studies in female Balb-c mice resulted in an LD10 value of 20 mg/kg (95% confidence limits; range, 19-21 mg/kg) and an LD50 value of 22 mg/kg (95% confidence limits; range, 21-23 mg/kg)." | ( The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. Calvert, AH; Foster, BJ; Graham, MA; Newell, DR, 1989) | 0.28 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " More recently, the use of preclinical pharmacokinetic information in mice has been proposed to also provide information that might expedite early clinical trials and more specifically phase I studies." | ( Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation. Calvert, AH; Foster, BJ; Graham, MA; Gumbrell, LA; Jenns, KE; Kaye, SB; Newell, DR, 1992) | 0.28 |
| " A total of 37 patients received 74 courses of CI-941 (5 to 55 mg/m2), with 26 patients consenting to pharmacokinetic monitoring." | ( Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. Calvert, AH; Foster, BJ; Graham, MA; Gumbrell, LA; Jenns, KE; Newell, DR, 1992) | 0.28 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Several subsequent series suggest that with cumulative dosing of 360 mg/m2 doxorubicin, the rate of CHF can be reduced to approximately 5%." | ( Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Kaufman, PA, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA topoisomerase 2-alpha | Homo sapiens (human) | IC50 (µMol) | 7.3000 | 0.4800 | 4.3564 | 9.9400 | AID381809 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (16)
Molecular Functions (13)
Ceullar Components (12)
Bioassays (12)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID381806 | Growth inhibition of human K562 cells after 72 hrs by MTS method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. |
| AID107943 | In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C to assess tumor growth delay (T-C) | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID381805 | Binding affinity to calf thymus DNA assessed as change in thermal stability at 2 uM in tris-HCl buffer at pH 7.5 by thermal denaturation assay | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. |
| AID381809 | Inhibition of human topoisomerase 2alpha decantation activity | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. |
| AID107947 | In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID381807 | Growth inhibition of etoposide-resistant human K/VP.5 cells after 72 hrs by MTS method | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. |
| AID153901 | In vivo antitumor activity against P388 leukemia cells at a dose of 12.5 mg/kg (single injection) and 25 mg/kg (Total ) | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID96628 | Antitumor activity against L1210 lymphocytic cells in vitro | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID381808 | Resistance factor, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7 | The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. |
| AID107944 | In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C to assess tumor growth delay (T-C) | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID107948 | In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| AID153902 | In vivo antitumor activity against P388 leukemia cells at a dose of 25 mg/kg as a single injection and 50 mg/kg as a total | 1984 | Journal of medicinal chemistry, Mar, Volume: 27, Issue:3 | 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (36)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 20 (55.56) | 18.2507 |
| 2000's | 9 (25.00) | 29.6817 |
| 2010's | 1 (2.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 15.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (15.91) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (17.50%) | 5.53% |
| Reviews | 2 (5.00%) | 6.00% |
| Case Studies | 1 (2.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||